Longevity Mediar’s new $76m funding advances anti-fibrosis treatmentsBy adminJanuary 17, 20260 Biotech raises oversubscribed Series B to advance first-in-class therapies for skin, lung and kidney scarring diseases. Boston biotech Mediar Therapeutics…
